Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Grifols SA ADR

GRFS
Current price
9.71 USD +0.02 USD (+0.21%)
Last closed 9.69 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 8 549 934 592 USD
Yield for 12 month +14.64 %
Week
Month
Year
GRFS
21.11.2021 - 28.11.2021

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain. Address: Avinguda de la Generalitat, 152, Barcelona, Spain, 08174

Analytics

WallStreet Target Price

16.33 USD

P/E ratio

247

Dividend Yield

7.09 %

Current Year

+6 639 833 083 USD

Last Year

+5 401 592 736 USD

Current Quarter

+1 749 187 262 USD

Last Quarter

+1 821 428 689 USD

Current Year

+2 443 447 783 USD

Last Year

+2 148 974 401 USD

Current Quarter

+691 835 173 USD

Last Quarter

+678 948 527 USD

Key Figures GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 978 580 992 USD
Operating Margin TTM 15.22 %
PE Ratio 247
Return On Assets TTM 1.81 %
PEG Ratio 0.4093
Return On Equity TTM 1.24 %
Wall Street Target Price 16.33 USD
Revenue TTM 6 535 173 120 USD
Book Value 9.03 USD
Revenue Per Share TTM 4.81 USD
Dividend Share
Quarterly Revenue Growth YOY 3.7 %
Dividend Yield 7.09 %
Gross Profit TTM 2 231 530 000 USD
Earnings Share 0.04 USD
Diluted Eps TTM 0.04 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -38.5 %
Profit Margin 0.36 %

Dividend Analytics GRFS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

52 %

Dividend History GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 0.91
Ex Dividend Date 03.06.2021
Forward Annual Dividend Yield 7.09 %
Last Split Factor 2:1
Payout Ratio
Last Split Date 04.01.2016
Dividend Date 14.06.2021

Stock Valuation GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 247
Forward PE 13.2802
Enterprise Value Revenue 3.0855
Price Sales TTM 1.2683
Enterprise Value EBITDA 17.442
Price Book MRQ 0.7986

Financials GRFS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators GRFS

For 52 weeks

6.5 USD 10.97 USD
50 Day MA 8.91 USD
Shares Short Prior Month 4 163 685
200 Day MA 8.83 USD
Short Ratio 7.81
Shares Short 4 786 227
Short Percent 0.4 %